[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fPT8u84dla-LHLQpeNNebJ12-ym4f-1F4u7Hg7eUknhE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":58,"rows":65},"Fundación para la Investigación del Hospital Clínico de Valencia",[4],67,false,16,3,23356,13,53,[14,17,20,22,24,26,29,31],{"name":15,"count":16},"Heart Failure",8,{"name":18,"count":19},"Gastric Cancer",4,{"name":21,"count":9},"Breast Cancer",{"name":23,"count":9},"Type 1 Diabetes",{"name":25,"count":9},"Lung Collapse",{"name":27,"count":28},"Chronotropic Incompetence",2,{"name":30,"count":28},"Heart Failure With Preserved Ejection Fraction",{"name":32,"count":28},"Magnetic Resonance",[34,39,44,49,53],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06578533","Keeping RAASi Treatment With Optimal Potassium Control","2025-07-30","Sodium Zirconium Cyclosilicate",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06578520","Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure","2025-12-01","Dapagliflozin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06851962","Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","2026-06-30","Metformin",{"nctId":50,"briefTitle":51,"date":52,"intervention":38},"NCT06578078","A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients","2026-12-30",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07476859","Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","2028-04","Ferric Carboxymaltose Injection [Ferinject]",[59,60,61,62,63,64],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[66,105,124,142,160,178,196,214,232,250,268,292,321,339,376,400,418,443,471,489,520,538,556,582,608,638],{"intervention":43,"totalTrials":28,"cells":67},{"EARLY_PHASE1":68,"PHASE1":71,"PHASE2":73,"PHASE3":75,"PHASE4":77,"NA":103},{"trials":69,"activeCount":70},[],0,{"trials":72,"activeCount":70},[],{"trials":74,"activeCount":70},[],{"trials":76,"activeCount":70},[],{"trials":78,"activeCount":28,"soonestReadout":42},[79,95],{"nctId":45,"briefTitle":46,"status":80,"phases":81,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":84,"interventions":86},"ACTIVE_NOT_RECRUITING",[63],"2025-05-26",504,[85],"Diabetes Mellitus Type 2",[48,87,88,89,90,43,91,92,93,94],"Dulaglutide","Semaglutide 1.0 mg","Empagliflozin","Canagliflozin","pioglitazone","Sitagliptin","Vildagliptin","linagliptin",{"nctId":40,"briefTitle":41,"status":96,"phases":97,"primaryCompletion":42,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":102},"RECRUITING",[63],"2025-12-31","2024-07-30",31,[15],[43],{"trials":104,"activeCount":70},[],{"intervention":48,"totalTrials":106,"cells":107},1,{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":122},{"trials":109,"activeCount":70},[],{"trials":111,"activeCount":70},[],{"trials":113,"activeCount":70},[],{"trials":115,"activeCount":70},[],{"trials":117,"activeCount":106,"soonestReadout":47},[118],{"nctId":45,"briefTitle":46,"status":80,"phases":119,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":120,"interventions":121},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":123,"activeCount":70},[],{"intervention":87,"totalTrials":106,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":127,"activeCount":70},[],{"trials":129,"activeCount":70},[],{"trials":131,"activeCount":70},[],{"trials":133,"activeCount":70},[],{"trials":135,"activeCount":106,"soonestReadout":47},[136],{"nctId":45,"briefTitle":46,"status":80,"phases":137,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":138,"interventions":139},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":141,"activeCount":70},[],{"intervention":88,"totalTrials":106,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":158},{"trials":145,"activeCount":70},[],{"trials":147,"activeCount":70},[],{"trials":149,"activeCount":70},[],{"trials":151,"activeCount":70},[],{"trials":153,"activeCount":106,"soonestReadout":47},[154],{"nctId":45,"briefTitle":46,"status":80,"phases":155,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":156,"interventions":157},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":159,"activeCount":70},[],{"intervention":89,"totalTrials":106,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":70},[],{"trials":165,"activeCount":70},[],{"trials":167,"activeCount":70},[],{"trials":169,"activeCount":70},[],{"trials":171,"activeCount":106,"soonestReadout":47},[172],{"nctId":45,"briefTitle":46,"status":80,"phases":173,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":174,"interventions":175},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":177,"activeCount":70},[],{"intervention":90,"totalTrials":106,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":188,"NA":194},{"trials":181,"activeCount":70},[],{"trials":183,"activeCount":70},[],{"trials":185,"activeCount":70},[],{"trials":187,"activeCount":70},[],{"trials":189,"activeCount":106,"soonestReadout":47},[190],{"nctId":45,"briefTitle":46,"status":80,"phases":191,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":192,"interventions":193},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":195,"activeCount":70},[],{"intervention":91,"totalTrials":106,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":212},{"trials":199,"activeCount":70},[],{"trials":201,"activeCount":70},[],{"trials":203,"activeCount":70},[],{"trials":205,"activeCount":70},[],{"trials":207,"activeCount":106,"soonestReadout":47},[208],{"nctId":45,"briefTitle":46,"status":80,"phases":209,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":210,"interventions":211},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":213,"activeCount":70},[],{"intervention":92,"totalTrials":106,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":230},{"trials":217,"activeCount":70},[],{"trials":219,"activeCount":70},[],{"trials":221,"activeCount":70},[],{"trials":223,"activeCount":70},[],{"trials":225,"activeCount":106,"soonestReadout":47},[226],{"nctId":45,"briefTitle":46,"status":80,"phases":227,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":228,"interventions":229},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":231,"activeCount":70},[],{"intervention":93,"totalTrials":106,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":248},{"trials":235,"activeCount":70},[],{"trials":237,"activeCount":70},[],{"trials":239,"activeCount":70},[],{"trials":241,"activeCount":70},[],{"trials":243,"activeCount":106,"soonestReadout":47},[244],{"nctId":45,"briefTitle":46,"status":80,"phases":245,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":246,"interventions":247},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":249,"activeCount":70},[],{"intervention":94,"totalTrials":106,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":260,"NA":266},{"trials":253,"activeCount":70},[],{"trials":255,"activeCount":70},[],{"trials":257,"activeCount":70},[],{"trials":259,"activeCount":70},[],{"trials":261,"activeCount":106,"soonestReadout":47},[262],{"nctId":45,"briefTitle":46,"status":80,"phases":263,"primaryCompletion":47,"completion":47,"start":82,"enrollment":83,"conditions":264,"interventions":265},[63],[85],[48,87,88,89,90,43,91,92,93,94],{"trials":267,"activeCount":70},[],{"intervention":57,"totalTrials":106,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":290},{"trials":271,"activeCount":70},[],{"trials":273,"activeCount":70},[],{"trials":275,"activeCount":70},[],{"trials":277,"activeCount":70},[],{"trials":279,"activeCount":106,"soonestReadout":56},[280],{"nctId":54,"briefTitle":55,"status":96,"phases":281,"primaryCompletion":56,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":289},[63],"2028-05","2026-03-05",538,[286,287,288],"Acute Coronary Syndromes (ACS)","Iron Deficiencies","Elderly (People Aged 65 or More)",[57],{"trials":291,"activeCount":70},[],{"intervention":38,"totalTrials":28,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":317,"NA":319},{"trials":295,"activeCount":70},[],{"trials":297,"activeCount":70},[],{"trials":299,"activeCount":70},[],{"trials":301,"activeCount":28,"soonestReadout":37},[302,310],{"nctId":50,"briefTitle":51,"status":96,"phases":303,"primaryCompletion":52,"completion":52,"start":304,"enrollment":305,"conditions":306,"interventions":308},[62],"2024-10-03",94,[15,307],"Chronic Kidney Diseases",[38,309],"Standard of care treatment",{"nctId":35,"briefTitle":36,"status":96,"phases":311,"primaryCompletion":37,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},[62],"2026-07-30","2022-09-30",78,[307],[38],{"trials":318,"activeCount":70},[],{"trials":320,"activeCount":70},[],{"intervention":309,"totalTrials":106,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":335,"NA":337},{"trials":324,"activeCount":70},[],{"trials":326,"activeCount":70},[],{"trials":328,"activeCount":70},[],{"trials":330,"activeCount":106,"soonestReadout":52},[331],{"nctId":50,"briefTitle":51,"status":96,"phases":332,"primaryCompletion":52,"completion":52,"start":304,"enrollment":305,"conditions":333,"interventions":334},[62],[15,307],[38,309],{"trials":336,"activeCount":70},[],{"trials":338,"activeCount":70},[],{"intervention":340,"totalTrials":28,"cells":341},"CA125 guided strategy",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":374},{"trials":343,"activeCount":70},[],{"trials":345,"activeCount":70},[],{"trials":347,"activeCount":70},[],{"trials":349,"activeCount":70},[],{"trials":351,"activeCount":70},[352,363],{"nctId":353,"briefTitle":354,"status":355,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT02643147","Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)","COMPLETED",[63],"2017-01-30","2015-01",170,[15],[340,340,362],"Conventional Strategy",{"nctId":364,"briefTitle":365,"status":355,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT02008110","Carbohydrate Antigen 125-guided Therapy in Heart Failure",[63],"2014-07","2015-05","2011-12",360,[15],[340,340,340,373,340],"Standard treatment strategy",{"trials":375,"activeCount":70},[],{"intervention":377,"totalTrials":106,"cells":378},"Ferric carboymaltose",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":398},{"trials":380,"activeCount":70},[],{"trials":382,"activeCount":70},[],{"trials":384,"activeCount":70},[],{"trials":386,"activeCount":70},[],{"trials":388,"activeCount":70},[389],{"nctId":390,"briefTitle":391,"status":355,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":12,"conditions":395,"interventions":397},"NCT03398681","Changes in Myocardial Iron After Iron Administration",[63],"2018-07-30","2017-05-01",[15,396],"Iron-deficiency",[377],{"trials":399,"activeCount":70},[],{"intervention":362,"totalTrials":106,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":416},{"trials":403,"activeCount":70},[],{"trials":405,"activeCount":70},[],{"trials":407,"activeCount":70},[],{"trials":409,"activeCount":70},[],{"trials":411,"activeCount":70},[412],{"nctId":353,"briefTitle":354,"status":355,"phases":413,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":414,"interventions":415},[63],[15],[340,340,362],{"trials":417,"activeCount":70},[],{"intervention":419,"totalTrials":106,"cells":420},"Controlled withdrawal of beta-blockers",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":441},{"trials":422,"activeCount":70},[],{"trials":424,"activeCount":70},[],{"trials":426,"activeCount":70},[],{"trials":428,"activeCount":70},[],{"trials":430,"activeCount":70},[431],{"nctId":432,"briefTitle":433,"status":355,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":440},"NCT03871803","β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)",[63],"2021-02-27","2018-10-01",52,[439,27],"Heart Failure With Normal Ejection Fraction",[419],{"trials":442,"activeCount":70},[],{"intervention":444,"totalTrials":106,"cells":445},"Sevoflurane",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":469},{"trials":447,"activeCount":70},[],{"trials":449,"activeCount":70},[],{"trials":451,"activeCount":70},[],{"trials":453,"activeCount":70},[],{"trials":455,"activeCount":70},[456],{"nctId":457,"briefTitle":458,"status":459,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":467},"NCT04359862","Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection","TERMINATED",[63],"2021-03-31","2020-04-16",19,[465,466],"Acute Respiratory Distress Syndrome","COVID19 Infection",[444,468],"Propofol",{"trials":470,"activeCount":70},[],{"intervention":468,"totalTrials":106,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":487},{"trials":474,"activeCount":70},[],{"trials":476,"activeCount":70},[],{"trials":478,"activeCount":70},[],{"trials":480,"activeCount":70},[],{"trials":482,"activeCount":70},[483],{"nctId":457,"briefTitle":458,"status":459,"phases":484,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":485,"interventions":486},[63],[465,466],[444,468],{"trials":488,"activeCount":70},[],{"intervention":490,"totalTrials":106,"cells":491},"Patients receive microporous polysaccharide hemospheres.",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":518},{"trials":493,"activeCount":70},[],{"trials":495,"activeCount":70},[],{"trials":497,"activeCount":70},[],{"trials":499,"activeCount":70},[],{"trials":501,"activeCount":70},[502],{"nctId":503,"briefTitle":504,"status":355,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":516},"NCT06824831","Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy",[63],"2022-07-01","2024-09-02","2020-06-01",120,[511,512,513,514,515],"Mastectomy","Lymphadenectomy","Breast Neoplasm Malignant Female","Breast Surgery","Seroma Following Procedure",[490,517],"Patients DO NOT receive microporous polysaccharide hemospheres.",{"trials":519,"activeCount":70},[],{"intervention":517,"totalTrials":106,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":536},{"trials":523,"activeCount":70},[],{"trials":525,"activeCount":70},[],{"trials":527,"activeCount":70},[],{"trials":529,"activeCount":70},[],{"trials":531,"activeCount":70},[532],{"nctId":503,"briefTitle":504,"status":355,"phases":533,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":534,"interventions":535},[63],[511,512,513,514,515],[490,517],{"trials":537,"activeCount":70},[],{"intervention":373,"totalTrials":106,"cells":539},{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":554},{"trials":541,"activeCount":70},[],{"trials":543,"activeCount":70},[],{"trials":545,"activeCount":70},[],{"trials":547,"activeCount":70},[],{"trials":549,"activeCount":70},[550],{"nctId":364,"briefTitle":365,"status":355,"phases":551,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":552,"interventions":553},[63],[15],[340,340,340,373,340],{"trials":555,"activeCount":70},[],{"intervention":557,"totalTrials":106,"cells":558},"Direct oral anticoagulant",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":560,"activeCount":70},[],{"trials":562,"activeCount":70},[],{"trials":564,"activeCount":70},[],{"trials":566,"activeCount":70},[],{"trials":568,"activeCount":70},[],{"trials":570,"activeCount":70},[571],{"nctId":572,"briefTitle":573,"status":355,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":581},"NCT03182218","Periprocedural Direct Oral Anticoagulant Management",[],"2018-02","2018-06","2015-02",1100,[580],"Periprocedural Complication",[557],{"intervention":583,"totalTrials":106,"cells":584},"Adenosine triphosphate",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":586,"activeCount":70},[],{"trials":588,"activeCount":70},[],{"trials":590,"activeCount":70},[],{"trials":592,"activeCount":70},[],{"trials":594,"activeCount":70},[],{"trials":596,"activeCount":70},[597],{"nctId":598,"briefTitle":599,"status":355,"phases":600,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":607},"NCT02789358","A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation",[64],"2016-06","2016-08","2015-12",140,[606],"Atrial Fibrillation",[583],{"intervention":609,"totalTrials":106,"cells":610},"High FiO2",{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":612,"activeCount":70},[],{"trials":614,"activeCount":70},[],{"trials":616,"activeCount":70},[],{"trials":618,"activeCount":70},[],{"trials":620,"activeCount":70},[],{"trials":622,"activeCount":70},[623],{"nctId":624,"briefTitle":625,"status":626,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":636},"NCT02776046","Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2).","UNKNOWN",[64],"2018-11","2019-02","2017-06-01",756,[633,634,635],"Hyperoxia","Postoperative Complication","Surgical Site Infection",[609,637],"Conventional FiO2",{"intervention":637,"totalTrials":106,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":641,"activeCount":70},[],{"trials":643,"activeCount":70},[],{"trials":645,"activeCount":70},[],{"trials":647,"activeCount":70},[],{"trials":649,"activeCount":70},[],{"trials":651,"activeCount":70},[652],{"nctId":624,"briefTitle":625,"status":626,"phases":653,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":654,"interventions":655},[64],[633,634,635],[609,637]]